Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

NCT01873534 is registered in ClinicalTrials.gov with FerruMax Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01873534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01873534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Lead sponsor
FerruMax Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2013
Completion date
March 31, 2014
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic disease